Announcement • 4h
Biosenta Inc. Highlights University of Calgary Research Validating Tri-Filler Antimicrobial Technology Biosenta Inc. highlighted new research released by the University of Calgary demonstrating the performance of the Company's antimicrobial nanotechnology, Tri-Filler, being developed in collaboration with researchers at the University of Calgary and the Alberta Centre for Advanced Diagnostics (ACAD). According to the University of Calgary, laboratory testing showed Tri-Filler achieved more than a 200-fold improvement in antibacterial performance compared with calcium hydroxide, a commonly used antimicrobial compound. The University also reported that early testing indicates the material maintained its structural integrity and antibacterial properties after more than one year under elevated temperature and humidity conditions. The findings were announced by the University of Calgary in an article describing the research collaboration and the technology's potential applications. The research was led by Dr. Maen Husein of the Schulich School of Engineering and Dr. Mehdi Mohammadi Ashani of the Department of Biological Sciences, with contributions from Dr. Reza Lashkari and Dr. Noora Darwish. The work was completed through a collaborative research program involving the University of Calgary, Biosenta and the Alberta Centre for Advanced Diagnostics. Biosenta has worked with the University research team over the past several years to advance Tri-Filler from laboratory development toward commercial applications. Tri-Filler is a proprietary core-shell antimicrobial technology designed for incorporation into coatings, paints, concrete and other building materials used in high-contact environments. The controlled-release design is intended to provide long-term antimicrobial performance within the material itself. According to the University of Calgary, potential applications include hospitals, schools, daycares, public transportation and other environments where reducing microbial contamination is important. The Companies expect the field test to produce structured observations and data that can help inform next steps for product development, partner engagement, and broader market adoption. Dr. Mehdi Mohammadi Ashani, Senior Scientist at Biosenta and a researcher in the University of Calgary's Department of Biological Sciences, said the collaboration has focused on evaluating Tri-Filler's performance and collecting data to inform further research and product development. Over the past several years, work has focused on evaluating Tri-Filler under conditions beyond initial laboratory testing. This includes assessing its performance and generating data relevant to product development and regulatory review. Biosenta's commercialization program includes continued product validation, manufacturing scale-up, regulatory activities and strategic industry partnerships intended to support future market introduction. Reported Earnings • May 31
Second quarter 2026 earnings released: CA$0.016 loss per share (vs CA$0.021 loss in 2Q 2025) Second quarter 2026 results: CA$0.016 loss per share (improved from CA$0.021 loss in 2Q 2025). Net loss: CA$528.3k (loss narrowed 22% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 04
First quarter 2026 earnings released: CA$0.018 loss per share (vs CA$0.018 loss in 1Q 2025) First quarter 2026 results: CA$0.018 loss per share (in line with 1Q 2025). Net loss: CA$595.8k (loss widened 1.4% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. 
